Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 3, 2011, Pages 527-532

  Kim, Jin Young ^a   Do, Young Rok ^a   Park, Keon Uk ^a,b   Kim, Jong Gwang ^c   Chae, Yee Soo ^c   Kim, Min Kyoung ^d   Lee, Kyung Hee ^d   Ryoo, Hun Mo ^e   Bae, Sung Hwa ^e   Baek, Jin Ho ^f   Song, Hong Suk ^a  

^a Dongsan Medical Center   (South Korea)

^b Dongguk University   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

^d Young Nam University Hospital   (South Korea)

^e Catholic University of Daegu   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

Author keywords

Chemotherapy; Cisplatin; Gastric cancer; Paclitaxel; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; PACLITAXEL; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE COURSE; DRUG COMBINATION; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PACLITAXEL; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL; TEGAFUR; TREATMENT OUTCOME;

EID: 79953781220     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1353-6     Document Type: Article

References (28)

1. P Boyle J Ferlay 2005 Cancer incidence and mortality in Europe, 2004 Ann Oncol 16 481 488 1:STN:280:DC%2BD2M%2FptVGrsA%3D%3D 10.1093/annonc/mdi098 15718248 (Pubitemid 40458328)
2. AM Murad FF Santiago A Petroianu, et al. 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41 1:STN:280:DyaK3s3osVGqtQ%3D%3D 10.1002/1097-0142(19930701)72:1<37:: AID-CNCR2820720109>3.0.CO;2-P 8508427 (Pubitemid 23182046)
3. S Pyrhonen T Kuitunen P Nyandoto, et al. 1995 Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591 1:STN:280:DyaK2M7os1ertg%3D%3D 10.1038/bjc.1995.114 7533517
4. B Glimelius K Ekstrom K Hoffman, et al. 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163 168 1:STN:280:DyaK2s3kslGqug%3D%3D 10.1023/A:1008243606668 9093725 (Pubitemid 27112884)
5. Y Maehara 2003 S-1 in gastric cancer: a comprehensive review Gastric Cancer 6 Suppl 1 2 8 10.1007/s10120-003-0232-9 12775012 (Pubitemid 36604648)
6. Y Sakata A Ohtsu N Horikoshi, et al. 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720 1:CAS:528:DyaK1cXntlShurw%3D 10.1016/S0959-8049(98)00211-1 9893658 (Pubitemid 28474225)
7. W Koizumi M Kurihara S Nakano, et al. 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197 1:CAS:528: DC%2BD3cXjvVeitr4%3D 10.1159/000012099 10765119 (Pubitemid 30189900)
8. P Chollet P Schoffski K Weigang-Kohler, et al. 2003 Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG) Eur J Cancer 39 1264 1270 1:CAS:528:DC%2BD3sXjvFelurs%3D 10.1016/S0959-8049(03)00237-5 12763215 (Pubitemid 36579198)
9. A Ohtsu N Boku F Tamura, et al. 1998 An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer Am J Clin Oncol 21 416 419 1:STN:280:DyaK1cznt1emsw%3D%3D 10.1097/00000421-199808000-00021 9708646 (Pubitemid 28366916)
10. Y Yamada K Shirao A Ohtsu, et al. 2001 Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133 1137 1:STN:280:DC%2BD3MrjsFehtQ%3D%3D 10.1023/A:1011680507956 11583196 (Pubitemid 32834495)
11. Y Emi M Yamamoto I Takahashi, et al. 2008 Phase II study of weekly palcitaxel by one-hour infusion for advanced gastric cancer Surg Today 38 1013 1020 1:CAS:528:DC%2BD1cXht12rtrnF 10.1007/s00595-008-3769-8 18958560
12. JG Kim SK Sohn HS Song, et al. 2007 Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer Cancer Chemother Pharmacol 60 863 869 1:CAS:528: DC%2BD2sXhtVWqur%2FJ 10.1007/s00280-007-0433-8 17333192 (Pubitemid 47389392)
13. JA Ajani J Fairweather P Dumas, et al. 1998 Phase II study of taxol in patients with advanced gastric carcinoma Cancer J Sci Am 4 269 274 1:STN:280:DyaK1czlsVCnsg%3D%3D 9689986
14. C Bokemeyer CS Lampe MR Clemens, et al. 1997 A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer Anticancer Drugs 8 396 399 1:CAS:528: DyaK2sXjsVyrs7g%3D 10.1097/00001813-199704000-00014 9180395 (Pubitemid 27204960)
15. MK Kim KH Lee MS Hyun, et al. 2005 A multi-center, phase II clinical trial of padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer Cancer Res Treat 37 349 353 10.4143/crt.2005.37.6.349 19956371
16. JJ Lee SY Kim HC Chung, et al. 2009 A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer Cancer Chemother Pharmacol 63 1083 1090 1:CAS:528:DC%2BD1MXjslOlu74%3D 10.1007/s00280-008-0818-3 18813927
17. H Narahara K Fujitani H Takiuchi, et al. 2008 Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer Oncology 74 37 41 1:CAS:528:DC%2BD1cXnvFSjs70%3D 10.1159/000138978 18544958 (Pubitemid 351915008)
18. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
19. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 1:STN:280:DyaL1M7ps1SjsQ%3D%3D 10.1016/0197-2456(89) 90015-9 2702835 (Pubitemid 19099520)
20. J Wils 1996 The treatment of advanced gastric cancer Semin Oncol 23 397 406 1:STN:280:DyaK283ktlSjtQ%3D%3D 8658224 (Pubitemid 26187740)
21. E Mochiki T Ohno Y Kamiyama, et al. 2006 Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer Br J Cancer 95 1642 1647 1:CAS:528:DC%2BD28Xht12ktbfL 10.1038/sj.bjc.6603497 17133268 (Pubitemid 44950789)
22. R Kawabata Y Fujiwara Y Doki, et al. 2007 Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer Oncology 72 219 225 1:CAS:528:DC%2BD1cXptlKksQ%3D%3D 10.1159/000112945 18176087 (Pubitemid 351161614)
23. S Inada T Tomidokoro H Fukunari, et al. 2009 Phase I/II trial of combination therapy with S-1 and weekly pacitaxel in patients with unresectable or recurrent gastric cancer Cancer Chemother Pharmacol 63 267 273 1:CAS:528:DC%2BD1cXhsVelurbO 10.1007/s00280-008-0736-4 18379784
24. JA Aajni FC Lee DA Singh, et al. 2006 Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 663 667 10.1200/JCO.2005.04.2994 (Pubitemid 46630431)
25. W Koizumi H Narahara T Hara, et al. 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221 1:CAS:528:DC%2BD1cXivVaqtb4%3D 10.1016/S1470-2045(08)70035-4 18282805
26. SR Park HK Kim CG Kim, et al. 2008 Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma Br J Cancer 98 1305 1311 1:CAS:528:DC%2BD1cXks12gurk%3D 10.1038/sj.bjc.6604312 18362939 (Pubitemid 351543578)
27. E Van Cutsem VM Moiseyenko S Tjulandin V325 Study Group, et al. 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997 10.1200/JCO.2006.06. 8429 17075117 (Pubitemid 46631401)
28. DH Ilson 2007 Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 25 3188 3190 1:CAS:528:DC%2BD2sXhtVWqs73I 10.1200/JCO.2006.10.2210 17664464 (Pubitemid 47325599)